Verdant Research provides independent, objective analysis to inform the future of U.S. prescription drug policy. We combine rigorous modeling with deep policy expertise to support smarter policy and business decisions in pharmaceutical markets.
Verdant provides economic and policy expertise across the core forces shaping U.S. prescription drug markets.
On January 27, 2026, the Centers for Medicare & Medicaid Services announced the next round of drugs to be negotiated by Medicare. This round includes 15 drugs withnegotiated prices going into effect in 2028…
Drug prices in the United States remain the highest in the world. New payment approaches are needed, a point illustrated by the new treatments for hepatitis C virus (HCV) infection that are highly effective but also very expensive, at least from the view of many payers, physicians, and patients…
Partner with Verdant for rigorous, objective economic analysis.